Viatris, a global healthcare company, MedAccess, and TB Alliance have announced a new agreement to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34%. Pretomanid is part of two new treatment regimens with high efficacy and shorter treatment durations recently recommended by the World Health Organization (WHO) as the preferred regimens for most drug-resistant tuberculosis patients. Read more here.
top of page
Recent Posts
See AllPhumeza Tisile was treated for MDR-TB in 2010 and suffered severe side effects from the drug, kanamycin. Her experiences drove her to...
110
The WHO has released new guidelines for prophylactic TB treatments. Among the updates to the guidelines are adjusted dosage...
90
The TB-CAPT consortium released a new study recently that showed that the new Xpert MTB/XDR testing can provide signigificantly faster...
140
bottom of page
Kommentare